Module COAG-03 · Version 1.0
Anticoagulants and Their Effects on Laboratory Tests
Anticoagulant drug classes act on different points in the clotting cascade, so PT, aPTT, thrombin time, and anti-Xa assays respond differently depending on which drug is present, which method is used, and which reagent is on the analyzer. Vitamin K antagonists, unfractionated and low-molecular-weight heparin, direct thrombin inhibitors, and factor Xa inhibitors map to the tests they affect, the dedicated assays used to measure them, and the specimen and reagent pitfalls that can mimic or mask an anticoagulant effect.
Your next section
Start section 1Read without an account. Sign in to save.
Who this module is for
Clinical laboratory scientists and trainees who perform or interpret coagulation testing on patients receiving anticoagulant therapy.
Learning objectives
- Distinguish vitamin K antagonists, unfractionated and low-molecular-weight heparins, direct thrombin inhibitors, and factor Xa inhibitors by mechanism and monitoring approach
- Predict the qualitative effect of each anticoagulant class on PT, aPTT, thrombin time, anti-Xa, mixing studies, and lupus-anticoagulant testing
- Select the drug history or drug-specific assay needed before interpreting an unexpected coagulation result
How completion works
Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.
Sources
12 sources
1. Clinical and Laboratory Standards Institute. H47: One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test, 3rd ed., H47Ed3E, March 7, 2023.
Source note · consensus standard
2. Clinical and Laboratory Standards Institute. H54-A: Procedures for Validation of INR and Local Calibration of PT/INR Systems, 1st ed. (archived but technically valid).
Source note · consensus standard
3. College of American Pathologists. All Common Checklist, COM.40300 Verification of Test Performance Specifications - FDA-cleared/approved (Phase II). CAP Accreditation Program, 12.09.2025 edition.
Source note · accreditation standard
4. Tripodi A, et al. Position Paper on laboratory testing for patients on direct oral anticoagulants. Blood Transfus. 2018;16:462-470. doi:10.2450/2017.0124-17.
Source note · professional society guidance
5. Bristol-Myers Squibb. ELIQUIS (apixaban) Prescribing Information, section 12.2, revised 2025.
Source note · manufacturer labeling
6. Boehringer Ingelheim. PRADAXA (dabigatran etexilate) Prescribing Information, section 12.2, Reference ID 5610543, 2025.
Source note · manufacturer labeling
7. Witt DM, et al. Guidance for the practical management of the heparin anticoagulants in treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41:165-186. doi:10.1007/s11239-015-1315-0.
Source note · professional society guidance
8. Bates SM, et al. American Society of Hematology 2018 guidelines: venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317-3359. doi:10.1182/bloodadvances.2018024802.
Source note · professional society guidance
9. Martini A, et al. Isolated prolongation of activated partial thromboplastin time: not just bleeding risk. Medicina. 2023;59:1169. doi:10.3390/medicina59071169.
Source note · peer-reviewed literature
10. De la Morena-Barrio ME, et al. Update on the laboratory diagnosis of lupus anticoagulant: current challenges and clinical involvement. J Clin Med. 2025;14:2791.
Source note · peer-reviewed literature
11. 42 CFR §493.1253, Standard: Establishment and verification of performance specifications, current eCFR text.
Source note · federal guidance
12. 42 CFR §§493.1251, 493.1255, and 493.1256, Standard: Procedure manual; Standard: Calibration procedures; Standard: Control procedures, current eCFR text.
Source note · federal guidance